Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper Cass Almendral (212) 838-1444 Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006
Delcath Systems to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
| Source: Delcath Systems, Inc.
NEW YORK, NY--(Marketwire - November 7, 2008) - Delcath Systems (NASDAQ : DCTH ), a leading
developer of regional therapy for cancer, announced today that their
President and CEO, Richard Taney, will present at the Rodman & Renshaw 10th
Annual Global Healthcare Conference in New York City on Monday, November
10, 2008 at 3:15 PM EST. The conference will be held at the New York
Palace Hotel.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company is testing a proprietary, patented drug
delivery system for the treatment of liver cancers. Delcath's novel drug
delivery platform is testing the delivery of ultra-high doses of
anti-cancer drugs to the liver while preventing these high doses of drug
from entering the patient's bloodstream. The Company is currently enrolling
patients in Phase III and Phase II clinical studies for the treatment of
liver cancers using high doses of melphalan. The Company's intellectual
property portfolio consists of twenty-eight patents on a worldwide basis
including the U.S., Europe, Asia and Canada. For more information, please
visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these forward
looking statements to reflect events or circumstances after the date they
are made.